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Implementation of an Outpatient, Pharmacist-Directed Clinic for Chronic
Obstructive Pulmonary Disease
Abstract
Objective: To describe development and challenges of implementing a pharmacist-led chronic obstructive
pulmonary disease (COPD) clinic in the primary care setting.
Methods
Methods: Starting in October 2014, patients scoring 10-30 on the COPD Assessment Test (CAT) were
assigned to the intervention or control group. Intervention patients met with a pharmacist, who provided
medication and lifestyle counseling and therapy recommendations to the patients’ primary provider per
protocol. Control patients were encouraged to make an appointment with their primary provider for
standard care. Two months following the initial CAT administration, the survey was administered again to
both study groups by phone. The primary outcome was a comparison of change in CAT scores from
baseline between the groups. Secondary outcomes included an analysis of medications, smoking status,
vaccination status, hospital stays, visit attendance, and self-evaluation of disease progression.
Results
Results: Of the 163 patients contacted, 29 were enrolled. Ninety-one percent of the patients screened with
the CAT were eligible based on the CAT requirement with an average baseline CAT score of 18.75. The
primary outcome, change in follow up CAT scores, were similar for intervention patients (n=18) versus
control patients (n=11), +0.8 versus +0.7 respectively. Four of the intervention patients attended their
clinic visit resulting in a 22% show rate.
Conclusion
Conclusion: Although our study was underpowered to detect between group differences, the elevated
baseline CAT scores support the need for therapy optimization in patients with COPD. Pharmacists are
well qualified to meet this need by providing medication counseling, smoking cessation, and therapy
management. Additional randomized controlled studies are needed to support improved outcomes for
patients with COPD when pharmacists are part of the clinical patient care team.
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Abstract
Objective: To describe development and challenges of implementing a pharmacist-led chronic
obstructive pulmonary disease (COPD) clinic in the primary care setting.
Methods: Starting in October 2014, patients scoring 10-30 on the COPD Assessment Test (CAT)
were assigned to the intervention or control group. Intervention patients met with a pharmacist, who
provided medication and lifestyle counseling and therapy recommendations to the patients’ primary
provider per protocol. Control patients were encouraged to make an appointment with their primary
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disease progression.
Results: Of the 163 patients contacted, 29 were enrolled. Ninety-one percent of the patients screened
with the CAT were eligible based on their CAT score with an average baseline score of 18.75. The
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Conclusion: Although our study was underpowered to detect between group differences, the elevated
baseline CAT scores support the need for therapy optimization in patients with COPD. Pharmacists
are well qualified to meet this need by providing medication counseling, smoking cessation, and
therapy management. Additional randomized controlled studies are needed to support improved
outcomes for patients with COPD when pharmacists are part of the clinical patient care team.
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Introduction
As the third leading cause of death in the United
States, the economic burden of chronic obstructive
pulmonary disease (COPD) is approximately $50 billion
in direct and indirect healthcare costs.1 This cost is
expected to increase as disease progression continues.1
With hospital stays from COPD exacerbations accounting
for the majority of this expense, optimal pharmacotherapy
to limit exacerbations is vitally important. Despite the
high cost of COPD exacerbations, Make and colleagues’
retrospective analysis of over 50,000 patients with either
commercial or Medicare insurance found that greater than
66% of privately insured patients and over 70% of the
Medicare population with COPD were not prescribed
standard maintenance COPD pharmacotherapy.2 Their
analysis found that the majority of patients were not
receiving any COPD medications, and merely 5%-7% of
patients were prescribed a short-acting β2-agonist,
standard of care therapy for all individuals with COPD.3
This study reveals that as many as 7 out of 10 patients
with COPD may benefit from inhaler treatment
optimization.
The impact of pharmacist involvement in the
management of COPD has been evaluated in several
recent studies in community and health-systems
settings.4,5,7-11
In a 2014 community-based study,
significant reduction in the use of high-dose steroid
therapy, an indicator of an acute exacerbation, was seen
with pharmacist-led interventions in patients with asthma
and COPD.4 This study involving over 109,000 patients
demonstrated improvements related to inhaler technique,
adherence to maintenance therapy, and cessation of
suboptimal medications.
Few studies have been conducted that evaluate
pharmacist intervention in the primary care setting. With
direct access to general practitioners, the ambulatory care
setting is especially conducive to the integration of
clinical pharmacy services with standard practice. One
study in this setting did show improvement in COPD
outcomes including hospitalization, adherence, and
disease knowledge; however, the study was unable to
detect a significant increase in health-related quality of
life.5 A drawback of the study was the utilization of the
St. George Respiratory Questionnaire (SGRQ), a 76-item
tool used to assess symptoms, activity, and impact.6
Although this tool is validated and designed for patients
with COPD, it is cumbersome and not practical for use by
healthcare providers on a routine basis. A 2014 metaanalysis focusing on the impact of pharmacist care for
outpatients with COPD yielded similar results. This
review by Zhong and colleagues’ included 8 randomized
controlled trials and supported positive pharmacist impact
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on medication adherence, hospital admission, and healthrelated costs.7
The aim of our study was to provide much
needed data on the impact of clinical pharmacists in the
primary care setting using methods that can feasibly be
replicated in general practice. The primary evaluation
tool used in our study was the COPD Assessment Test
(CAT). This 8-question, validated test allows for scores
from 0-40 with higher numbers indicating poorer COPD
control.12 The questionnaire is designed to assess
symptoms using a 1-5 scoring system that a patient could
self-administer. Patients scoring 10-30 on the CAT
indicate that they are at a medium to high risk of a COPD
exacerbation and were the target population for this study.
A 2-point change in CAT score is considered a significant
difference.13,14 The CAT user guide recommends for
patients to be routinely screened with the test every 2 to 3
months based on the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines.3 Positive
trial results would support the expansion of clinical
services offered by ambulatory care clinical pharmacists
while strengthening collaboration with general
practitioners to optimize patient care. Challenges faced
in this study were also examined to aid in the
implementation and enhancement of future pharmacistdirected, outpatient COPD management clinics.
Methods
This prospective pilot study was conducted
within a private family physician practice with 2 separate
clinical sites in West Tennessee. Following institutional
review board approval in September of 2014, the clinic’s
information technology department created a patient call
list for study recruitment. The study inclusion criteria
required patients to be at least 40 years of age, to have a
current diagnosis of COPD based on active ICD-9 codes,
and to score 10-30 on the COPD Assessment Test (CAT).
Patients were excluded if they were unable to complete
the CAT or provide informed consent, non-English
speaking, or pregnant. Patients were also excluded if their
CAT score was less than 10, indicating a low exacerbation
risk, or greater than 30, indicating very high risk.13
Patients scoring greater than 30 were encouraged to meet
with their primary care physician (PCP) for referral to a
pulmonary specialist. Nine of the PCPs within the
practice signed the study protocol, allowing their patients
to be enrolled in the study.
The patient call list contained the names and
phone numbers of clinic patients who met the age and
diagnosis requirements of the study and had visited their
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participating PCP in the last 2 years. These patients were
initially administered the CAT by phone from October
through November of 2014. A standardized patient phone
script was used to recruit patients. Study enrollees were
originally assigned in a 1:1 ratio to either the intervention
group or control group. The intervention group patients
were scheduled to meet with the pharmacy resident for a
face-to-face visit at their PCP’s clinic location. The
control group was encouraged to make an appointment
with their PCP for standard care. Due to the low clinic
visit show rate in the intervention group, patients were
assigned to the intervention group at an increased ratio in
the latter half of study recruitment. In both groups, a
follow up CAT was to be administered 2 months from the
initial CAT.
The intervention visit with the pharmacist
followed a standardized protocol that included a COPD
staging assessment based on the GOLD guidelines.3 The
visit included a review of relevant medical history, inhaler
technique evaluation, smoking cessation counseling,
exercise coaching, and immunization recommendations
as needed. Pharmacist recommendations to optimize
COPD inhaler therapy were discussed with the PCP prior
to initiation and followed a standardized protocol.
Patients were also provided with an individualized goal
sheet and visit summary.
The primary outcome of our study was an
intention-to-treat comparison of changes in CAT scores
from baseline between the intervention and standard care
groups. Secondary outcomes include an analysis of
COPD medications, smoking status, vaccination status,
hospital stays, clinic visit attendance, and self-evaluation
of disease progression.
Results
Twenty-nine patients were enrolled in the study
with 18 and 11 patients assigned to the intervention group
and control group respectively (Figure 1). Forty-six
percent (n=30) of the patients who were successfully
contacted by phone denied a diagnosis of COPD. These
patients confirmed lack of current inhaler use or
breathing-related health problems. Of the remaining 104
patients called, the majority either had wrong numbers
recorded in the clinic’s database or were unable to be
reached by phone. Three patients were no longer patients
of the participating providers. Three patients did not
qualify based on their CAT scores of 5, 6, and 31
respectively. The patient with a score greater than 30 was
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referred to the PCP for evaluation and potential follow up
with a pulmonary specialist per the study protocol.
Four of the eighteen patients in the intervention
group attended their scheduled pharmacist clinic visit,
resulting in a show rate of 22%. Fifty-seven percent of
the control group attended an appointment with their PCP
in between the initial and follow up CAT. The follow up
CAT was completed in 89% (n=16) and 64% (n=7) of the
intervention and control group subjects respectively.
Figure 1. Study
Progression

Population

Recruitment

and

163 Patients Called

60% Unable to
Reacha (n=98)

40% Reached
Successfully (n=65)

18% Denied COPD

18% Enrolled

4% Ineligibleb

(n=30)

(n=29)

(n=6)

Intervention Group

Control Group

(n=18)

(n=11)

22% Attended Clinic
Visit (n=4)

57% Attended PCP
Visit (n=4)

Follow Up
Completed

Follow Up
Completed

89% (n=16)

64% (n=7)

aPatients

were unable to be reached by phone due to either inaccurate
phone numbers or not answering the phone.
bOf the 6 ineligible patients, 3 patients had changed primary care
providers, and 3 patients were excluded due to CAT scores of 5, 6,
and 31.

The average initial CAT score in the intervention
group was 20.6 and 16.9 in the control group (Table 1).
The 2-month follow up CAT score was 21.4 and 17.6 in
the intervention and control groups respectively. The
primary outcome, difference in CAT scores from
baseline, was an increase of 0.8 in the intervention group
versus an increase of 0.7 in the control group.
Information collected on secondary outcomes is included
in Table 2. Three of the intervention group patients
reported that they felt their COPD symptoms had
improved two months from the initial CAT versus zero
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patients in the control group. The intervention group was
comprised of 50% active tobacco users versus 9% in the
control group.
Table 1. Comparison of CATa Scores
Average CAT
Intervention Group
Scores
(SDb)
Initial
20.6 (4.3)
2-Month Follow
21.6 (6.0)
Up
Difference
+0.8 (5.5)

Control Group
(SD)
16.9 (4.3)
17.6 (4.9)
+0.7 (2.3)

bSD

= standard deviation
aCAT = Chronic Obstructive Pulmonary Disease Assessment Test

Table 2. Comparison of Secondary Data Collection
Outcome
Intervention
Control
Group (%)
Group (%)
N=18
N=11
Perceived Change in
COPD Control
Worsened
4 (22)
3 (27)
Improved
3 (17)
0 (0)
Same
11 (61)
8 (73)
Tobacco Cessation
1 (6)
0 (0)
During Study
Medication Change
4 (22)a
2 (18)b
Vaccinations Received
1 (6)
0 (0)
Hospital Stays
1 (6)
1 (9)
aPercentages

based on intent-to-treat analysis out of the total number
of patients enrolled. Patients lost to follow up assessment were
included in percent calculations with no change in secondary items.
bMedication changes include initiation of 2 albuterol inhalers and 1
tiotropium inhaler
cMedication change included initiation of an ipratropium/albuterol
combination inhaler and one steroid dose pack

Discussion
There were several challenges and limitations
identified during this study. The primary limitation was
our inability to run statistics due to the small sample size.
A decrease in the 2-month CAT score of at least 2 points
from baseline would have supported the benefit of
pharmacist intervention from standard care. In our study,
the 2-month CAT scores for both groups increased
slightly. Although the significance of this less than 1point increase cannot be determined, we have identified
several potential contributing factors. Firstly, baseline
characteristics were dramatically different between
groups. For example, 50% of the intervention group
reported to be active smokers compared to 9% in the
control group. Also, the average initial CAT score in the
intervention group was 3.7 points higher than in the
control group. Secondly, the subjective nature of the CAT
may have led to non-COPD related changes in CAT
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scores. While these outliers may not impact the integrity
of overall CAT scores for a large study population, our
small cohort was especially vulnerable to potential
confounders. For example, 2 of the intervention patients
reported factors such as a heart failure exacerbation and
family stress as the causes for the worsening of their
COPD symptoms. Lastly, the CAT score did not
consistently reflect our patients’ perceived change in
COPD control. Although 2-month follow up CAT scores
did not improve, 3 of the intervention group patients
reported improvement in the COPD control while no
patients reported improvement in the control group.
Perceived COPD control and quality of life are areas for
future research.
The main contributor to our limited study size
was slow patient enrollment. Patient screening was based
on ICD-9 codes to eliminate the initial time lag associated
with reliance on provider referral. Although this approach
allowed the pharmacist to recruit patients immediately
upon study approval, it resulted in a time-consuming
recruitment process. Only 40% of the patients called were
successfully reached by phone. Of those patients
successfully reached, about half denied a diagnosis of
COPD. Patients who denied having COPD confirmed
that they currently had no difficulty breathing and were
not using any type of inhaler therapy. This discrepancy
in confirmed diagnosis of COPD and ICD-9 codes was
consistent with that seen in a study by Cooke and
colleagues.15 As a solution to reduce this administration
error, Cooke’s analysis supports using a combination
approach such as ICD-9 codes and chart documentation
of COPD medication prescriptions. A limitation of this
method is that it excludes patients with COPD who are
not currently prescribed COPD medications but who may
benefit from therapy initiation. A similar limitation
would be faced with requiring pulmonary function tests.
While greater reliance would be placed on provider
support, physician referral to a pharmacist-led COPD
clinic would bypass these challenges.
In addition to slow recruitment, clinic visit
attendance was low in both study arms. As seen in figure
1, 4 patients in each study group attended a clinic visit
during the study. Although reasons for clinic no-shows
varied, lack of transportation was reported to be a
common barrier to visit attendance. Clinic room space
and availability limited flexibility for scheduling
appointments as well. Neither of the clinic sites were the
pharmacists’ main practice sites, limiting flexibility for
rescheduling or impromptu appointments. The low show
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rate could also indicate low health literacy or inaccurate
beliefs regarding disease state severity and the possibility
of improved symptoms control. In a cohort by Kale and
colleagues, low health literacy was associated with illness
beliefs that were determinants for decreased adherence to
self-management and COPD medications.16 These issues
again may potentially be mitigated by physician referral
to the COPD management service along with scheduling
these pharmacist visits in conjunction with provider visits
to reduce travel burden.
The high cost of inhaler therapy was an additional
barrier identified in our patient population. Patients were
reluctant to initiate and adhere to expensive medication
therapy. Providers were sometimes hesitant to prescribe
these high cost COPD treatments, especially in patients
with concomitant health issues and many additional
medications. The pharmacist’s role in navigating patients
through the medication assistance process and consequent
impact on patient adherence and provider outlook is a
potential avenue for future research.
Lastly, primary care provider support was a key
factor in our study. As with all new services, the benefit
of the service needs to be effectively communicated to
both the patients and their providers. In our experience,
the vast majority of providers welcomed pharmacist
involvement in spending focused time with their patients
to optimize COPD therapy. For future study, utilization
of provider support of this service could potentially
improve the patient recruitment processes as well as visit
attendance.
Conclusion
The study’s sample size was underpowered to
apply a statistical analysis for primary and secondary
endpoints. However, the study did strongly support the
need for optimization of COPD therapy in our patient
population with CAT scores in 9 out of 10 patients
indicating a medium to high risk of a COPD exacerbation.
Our study identified that despite an initial lag time,
recruitment by provider referral could provide several
benefits. Provider referral could potentially reduce
recruitment time, labor, and administrative screening
error while increasing patients’ perceived value of the
service. In addition, coupling pharmacist-led, COPD
clinic visits with provider appointments could be an
effective method to improve patient show rate. Areas for
future COPD study include maximizing provider support,
evaluating the pharmacist’s role in the medication
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assistance process, and assessing patient beliefs regarding
disease state severity and the possibility of improved
symptoms control.
References
1. Guarascio AJ, Ray SM, Finch CK, et al. The
clinical and economic burden of chronic
obstructive pulmonary disease in the USA.
Clinicoecon Outcomes Res. 2013;5:235-45.
2. Make B, Dutro MP, Paulose-Ram R, et al.
Undertreatment of COPD: a retrospective
analysis of US managed care and Medicare
patients. Int J Chron Obstruct Pulmon Dis.
2012;7:1-9.
3. Global Initiative for Chronic Obstructive Lung
Disease: Global Strategy for the Diagnosis,
Management, and Prevention of Chronic
Obstructive Pulmonary Disease (Updated 2015).
www.goldcopd.org (Accessed 15 June 2015).
4. Ottenbros S, Teichert M, de Groot R, et al.
Pharmacist-led intervention study to improve
drug therapy in asthma and COPD patients. Int J
Clin Pharm. 2014;36(2):336-44.
5. Jarab AS, Alqudah SG, Khdour M, et al. Impact
of pharmaceutical care on health outcomes in
patients with COPD. Int J Clin Pharm.
2012;34(1):53-62.
6. Jones PW, Quirk FH, Baveystock CM,
Littlejohns P. A self- complete measure of health
status for chronic airflow limitation. The St.
George’s Respiratory Questionnaire. Am Rev
Respir Dis. 1992;145:1321–7.
7. Zhong H1, Ni XJ, Cui M, et al. Evaluation of
pharmacist care for patients with chronic
obstructive pulmonary disease: a systematic
review and meta-analysis. Int J Clin Pharm.
2014;36(6):1230-40
8. Van Boven JF, Tommelein E, Boussery K, et al.
Improving inhaler adherence in patients with
Chronic Obstructive Pulmonary Disease: a costeffectiveness analysis. Respir Res. 2014;15:66.
9. Khdour MR, Agus AM, Kidney JC, et al. Costutility analysis of a pharmacy-led selfmanagement programme for patients with COPD.
Int J Clin Pharm. 2011;33(4):665-73.
10. Hämmerlein A, Müller U, Schulz M. Pharmacistled intervention study to improve inhalation
technique in asthma and COPD patients. J Eval
Clin Pract. 2011;17(1):61-70.
11. Takemura M, Mitsui K, Ido M, et al. Effect of a
network system for providing proper inhalation
technique by community pharmacists on clinical

Excerpts in Pharmacy Research Journal Vol. 2 No. 1 (2016)

12.

13.

14.

15.

16.

outcomes in COPD patients. Int J Chron Obstruct
Pulmon Dis. 2013;8:239-44. Qual Life Res.
2014;23(4):1193-7.
Jones PW, Tabberer M, Chen W. Creating
scenarios of the impact of COPD and their
relationship to COPD assessment test (CATTM)
scores. BMC Pulmonary Medicine 2011; 11: 42.
Kon SS, Canavan JL, Jones SE, et al. Minimum
clinically important difference for the COPD
Assessment Test: a prospective analysis. Lancet
Respir Med. 2014;2(3):195-203.
Jones PW, Bruselle G, Dal Negro RW, et al.
Properties of the COPD assessment test in a
cross-sectional European study. Eur Respir J
2011; 38: 29-35
Cooke CR, Joo MJ, Anderson SM, et al. The
validity of using ICD-9 codes and pharmacy
records to identify patients with chronic
obstructive pulmonary disease. BMC Health Serv
Res. 2011;11:37.
Kale MS, Federman AD, Krauskopf K, et al. The
association of health literacy with illness and
medication beliefs among patients with chronic
obstructive pulmonary disease.
PLoS One. 2015; 10(4).

5|Page

